Nomura has maintained a 'Buy' rating on Indus Towers. The brokerage has kept its target price unchanged at ₹505, implying an upside of 30 per cent from its previous close of ₹388.55.
Piramal Pharma said that the US FDA has issued an Establishment Inspection Report (EIR) for its Sellersville facility, and the inspection has now been successfully closed.
Q1FY27 aviation preview: Key monitorables, Elara Capital said, are the extent of impact on international operations and rise in fuel/non-fuel costs from lower aircraft utilisation & rupee weakening
Motilal Oswal Financial Services has reiterated its 'Buy' rating on Eternal stock for a target price of ₹380, implying an upside of 31 per cent from its current price.
